Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Health Industry Watch.
Press releases published on May 5, 2025
DBV Technologies to Participate in the Citizens JMP Life Sciences Conference
GlobeNewswire
·
May 5, 2025
Châtillon, France, May 5, 2025 DBV Technologies to Participate in the Citizens JMP Life Sciences Conference DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced …
DBV Technologies participera à la conférence Citizens JMP Life Sciences
GlobeNewswire
·
May 5, 2025
Châtillon, France, le 5 mai (22 :30 CEST) 2025 DBV Technologies participera à la conférence Citizens JMP Life Sciences DBV Technologies (Euronext : DBV – ISIN : FR0010417345 – Nasdaq Stock Market : DBVT), société biopharmaceutique en phase clinique, …
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
May 5, 2025
MALVERN, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from …
Anaptys Announces First Quarter 2025 Financial Results and Provides Business Update
GlobeNewswire
·
May 5, 2025
Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the first week of June Initial Phase 2 data for rosnilimab in …
Certara Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today reported its financial results for the first quarter of fiscal year 2025. First Quarter Highlights: Revenue was $106.0 …
SI-BONE, Inc. Reports Financial Results for the First Quarter 2025 and Updates 2025 Guidance
GlobeNewswire
·
May 5, 2025
First Quarter 2025 Financial Highlights (all comparisons are to the prior year period) Worldwide revenue of $47.3 million, representing growth of 24.9% U.S. revenue of $44.8 million, representing growth of 26.6% Gross margin of 79.7%, representing an …
Castle Biosciences Reports First Quarter 2025 Results
GlobeNewswire
·
May 5, 2025
Q1 2025 revenue increased 21% over Q1 2024 to $88 million Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024 Raising full-year 2025 revenue guidance to $287-297 million …
Context Therapeutics Announces Chief Medical Officer Transition
GlobeNewswire
·
May 5, 2025
PHILADELPHIA, May 05, 2025 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging bispecific antibodies for solid tumors, today announced Dr. Karen Smith, …
Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewswire
·
May 5, 2025
Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for …
Castle Biosciences to Acquire Previse
GlobeNewswire
·
May 5, 2025
Expected to complement Castle’s current gastroenterology franchise Adds methylation technology developed at the Johns Hopkins University School of Medicine and additional technologies in development FRIENDSWOOD, Texas, May 05, 2025 (GLOBE NEWSWIRE) -- …
Mineralys Therapeutics to Announce First Quarter 2025 Financial Results and Host Conference Call on Monday, May 12, 2025
GlobeNewswire
·
May 5, 2025
RADNOR, Pa., May 05, 2025 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD), obstructive sleep apnea (OSA) and …
FibroGen to Report First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
SAN FRANCISCO, May 05, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce first quarter 2025 financial results on Monday, May 12 after the markets close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time …
Biomea Fusion Reports First Quarter 2025 Financial Results and Corporate Highlights
GlobeNewswire
·
May 5, 2025
Company Announces Strategic Realignment to Focus on Core Programs and Extend Cash Runway Icovamenib progressing toward the next phase of clinical development in insulin deficient type 2 diabetes patients and patients that are currently uncontrolled on a …
Tactile Systems Technology, Inc. Reports First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”; the “Company”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today reported financial results for the …
ORIC® Pharmaceuticals Reports First Quarter 2025 Financial Results and Operational Updates
GlobeNewswire
·
May 5, 2025
Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best-in-class profile of ORIC-944 in combination with AR …
uniQure to Announce First Quarter 2025 Financial Results
GlobeNewswire
·
May 5, 2025
LEXINGTON, Mass. and AMSTERDAM, the Netherlands, May 05, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs will report first quarter 2025 financial …
Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
May 5, 2025
- Progression-free survival data from more than 30 patients with first line pancreatic cancer in the ongoing Phase 2a trial of IMM-1-104 trial planned for announcement in 2Q’25 - - Reported positive data from the Company’s ongoing Phase 2a trial of lead …
Inspire Medical Systems, Inc. Announces First Quarter 2025 Financial Results and Updates 2025 Outlook
GlobeNewswire
·
May 5, 2025
Inspire Reports Year-over-Year Revenue Growth of 23% and Earnings per Share of $0.10 in the First Quarter MINNEAPOLIS, May 05, 2025 (GLOBE NEWSWIRE) -- Inspire Medical Systems, Inc. (NYSE: INSP) (Inspire, or the company), a medical technology company …
Celldex Presents Histology Data from Phase 2 Study of Barzolvolimab in EoE Supporting Potential of Mast Depleting Agent in this Difficult to Treat Disease
GlobeNewswire
·
May 5, 2025
HAMPTON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Celldex announced today the presentation of histology data from the Company’s ongoing Phase 2 study of barzolvolimab in eosinophilic esophagitis (EoE). Biopsies taken during screening demonstrate the presence …
Editas Medicine to Announce First Quarter 2025 Financial Results and to Participate in Investor Conference in May
GlobeNewswire
·
May 5, 2025
CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial …